Generic and therapeutic substitutions in the UK: Are they a good thing?

British Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2010, Pages 335-341

  Duerden, Martin G ^a   Hughes, Dyfrig A ^b  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Bioequivalence; Cost minimization analysis; Generic substitution; Therapeutic equivalence; Therapeutic substitution

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ANTACID AGENT; APOMORPHINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BISOPROLOL FUMARATE; BUPRENORPHINE; CARBAMAZEPINE; CARDICOR; CLENIL MODULITE; CYCLOSPORIN A; CYPROTERONE; CYPROTERONE ACETATE; DILTIAZEM; DULOXETINE; ESTRADIOL; FENTANYL; GENERIC DRUG; HORMONE; HUMAN GROWTH HORMONE; INSULIN; LITHIUM; MESALAZINE; MORPHINE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PANCREATIN; PHENYTOIN; PROSTAGLANDIN E1; SILDENAFIL; SIMETHICONE; TACROLIMUS; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COST MINIMIZATION ANALYSIS; DRUG COST; DRUG INDICATION; DRUG SELF ADMINISTRATION; GENERAL PRACTITIONER; HEALTH SERVICE; HORMONE SUBSTITUTION; INHALER; MEDICATION ERROR; PATIENT COMPLIANCE; PHARMACIST; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG UTILIZATION; DRUGS, GENERIC; GREAT BRITAIN; HUMANS; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 77955741424     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03718.x     Document Type: Review

References (40)

1. House of Commons Committee of Public Accounts. Department of Health: Prescribing costs in primary care. December 2007. Available at http://www.parliament.uk/parliamentary-committees/committee-of-public-accounts/ pacpn070117.cfm (last accessed 5 July 2010).
2. Goldsmith D, Duerden M. Statins: to switch or not to switch? Prescriber 2008 19 : 35 41.
3. Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet 2007 369 : 27.
4. National Audit Office. Prescribing costs in primary care. May 2007. Available at http://www.nao.org.uk/publications/0607/prescribing-costs-in- primary-c.aspx (last accessed 5 July 2010).
5. Institute for Innovation and Improvement. NHS Better Care, Better Value Indicators. Available at http://www.productivity.nhs.uk/default.aspx (last accessed 5 July 2010).
6. National Audit Office. Prescribing Savings in 2008. http://www.nao.org. uk/publications/0809/prescribing-savings-in-2008.aspx (last accessed 5 July 2010).
7. Department of Health. Strategies to achieve cost-effective prescribing: Interim Guidance for Primary Care Trusts. June 2007. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-076350?IdcService=GET-FILE&dID= 143220&Rendition=Web (last accessed 5 July 2010).
8. Department of Health. The proposals to implement 'generic substitution' in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009. Consultation document 2010. Available at http://www.dh.gov.uk/en/ Consultations/Liveconsultations/DH-110517 (last accessed 5 July 2010).
9. The Association of the British Pharmaceutical Industry. Generic substitution: patient safety comes first. http://www.abpi.org.uk/press/press- releases-10/050110.asp (last accessed 5 July 2010).
10. Department of Health. Building on the best: Choice, responsiveness and equity in the NHS. 2003. Available at http://www.dh.gov.uk/en/Consultations/ Responsestoconsultations/DH-4068391 (last accessed 5 July 2010).
11. NHS Choices. http://www.nhs.uk/choiceintheNHS/Yourchoices/allaboutchoice/ Pages/Allaboutchoice.aspx (last accessed 5 July 2010).
12. One Voice Wales. http://www.onevoicewales.org.uk/news/new-nhs-structure- for-wales (last accessed 5 July 2010).
13. BNF. British National Formulary Extra 2010. Name changes. Available at http://bnf.org/bnf/extra/current/450049.htm (last accessed 5 July 2010).
14. Committee for Proprietary Medicinal Products. Notes for Guidance on the Investigation of Bioavailability and Bioequivalence. London : European Medicines Evaluation Agency, 2001.
15. Joint Formulary Committee. British National Formulary No 59. London : British Medical Association, Royal Pharmaceutical Society of Great Britain, 2010.
16. Williamson IJ, Reid A, Monei RD, Fennerty AG, Rimmer EM. Generic inhaled salbutamol versus branded salbutamol. A randomised double-blind study. Postgrad Med J 1997 73 : 156 158.
17. Himmel W, Simmenroth-Nayda A, Neibling W, Ledig T, Jansen RD, Kochen MM, Gleiter CH, Hummers-Pradier E. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005 43 : 472 479.
18. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008 300 : 2514 2526.
19. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010 70 : 605 621.
20. Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009 14 : 150 153.
21. Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R. Clinical Guidelines and Evidence Review for the Epilepsies: Diagnosis and Management in Adults and Children in Primary and Secondary Care. London : Royal College of General Practitioners, 2004.
22. Scottish Intercollegiate Guidelines Network. Diagnosis and Management of Epilepsy in Adults. Guideline No 70. Edinburgh : Diagnosis and management of epilepsy in adults, 2003.
23. Department of Health. Treatment for epilepsy: generic lamotrigine. March 2005. Available at http://www.dh.gov.uk/en/Healthcare/ Medicinespharmacyandindustry/Prescriptions/DH-4104966 (last accessed 5 July 2010).
24. Epilepsy Action. Continuity of drugs. Available at http://www.epilepsy. org.uk/info/drugs-change.html (accessed 5 July 2010).
25. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004 351 : 1403 1408.
26. European Medicines Agency. Guideline on similar biological medicinal products. November 2004. Available at http://www.ema.europa.eu/pdfs/human/ biosimilar/043704en.pdf (last accessed 5 July 2010).
27. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. February 2006. Available at http://www.ema.europa.eu/pdfs/human/ biosimilar/4934805en.pdf (last accessed 5 July 2010).
28. Hughes DA. Biosimilars: evidential standards for health technology assessment. Clin Pharmacol Ther 2010 87 : 257 261.
29. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). October 2008. Available at http://www.ema.europa.eu/pdfs/human/pcwp/7456206en.pdf (last accessed 5 July 2010).
30. Phillips B, Roberts C, Rudolph AE, Morant S, Aziz F, O'Regan CP. Switching statins: the impact on patient outcomes. Br J Cardiol 2007 14 : 280 285.
31. Hickman J. Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention? Br J Gen Pract 2010 60 : 50 2.
32. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008 62 : 480 484.
33. Nelson AL, Cohen JT, Greenberg D, Kent DM. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med 2009 151 : 662 667.
34. Anon. Drug and Therapeutics Bulletin. Which statin, what dose? Drug Ther Bull 2007 45 : 33 6.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvasatatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
36. National Institute for Health and Clinical Excellence. Clinical Guideline Number 67. May 2008. Available at http://www.nice.org.uk/CG067 (last accessed 5 July 2010).
37. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1423.
38. Duerden MG. Making sense of drug pricing. WeMeReC Online resources. 2006. Available at http://www.wemerec.org/Documents/enotes/MedicinesPricing.pdf (last accessed 5 July 2010).
39. Hughes DA, Ferner RE. New drugs for old: disinvestment and NICE. BMJ 2010 340 : c572.
40. UK Medicines Information. Which medicines are not suitable for generic prescribing in primary care? Q&A 247.1. Liverpool : North West Medicines Information Centre, 2009.